153 related articles for article (PubMed ID: 9215314)
1. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases.
Belfiore A; Gangemi P; Costantino A; Russo G; Santonocito GM; Ippolito O; Di Renzo MF; Comoglio P; Fiumara A; Vigneri R
J Clin Endocrinol Metab; 1997 Jul; 82(7):2322-8. PubMed ID: 9215314
[TBL] [Abstract][Full Text] [Related]
2. Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy.
Ippolito A; Vella V; La Rosa GL; Pellegriti G; Vigneri R; Belfiore A
Thyroid; 2001 Aug; 11(8):783-7. PubMed ID: 11525273
[TBL] [Abstract][Full Text] [Related]
3. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
[TBL] [Abstract][Full Text] [Related]
4. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.
Mineo R; Costantino A; Frasca F; Sciacca L; Russo S; Vigneri R; Belfiore A
Endocrinology; 2004 Sep; 145(9):4355-65. PubMed ID: 15192042
[TBL] [Abstract][Full Text] [Related]
5. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma.
Ramirez R; Hsu D; Patel A; Fenton C; Dinauer C; Tuttle RM; Francis GL
Clin Endocrinol (Oxf); 2000 Nov; 53(5):635-44. PubMed ID: 11106926
[TBL] [Abstract][Full Text] [Related]
6. Expression of Met protein in thyroid tumours.
Ruco LP; Ranalli T; Marzullo A; Bianco P; Prat M; Comoglio PM; Baroni CD
J Pathol; 1996 Nov; 180(3):266-70. PubMed ID: 8958803
[TBL] [Abstract][Full Text] [Related]
7. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis.
Ruco LP; Stoppacciaro A; Ballarini F; Prat M; Scarpino S
J Pathol; 2001 May; 194(1):4-8. PubMed ID: 11329134
[TBL] [Abstract][Full Text] [Related]
8. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas.
Trovato M; Grosso M; Vitarelli E; Ruggeri RM; Alesci S; Trimarchi F; Barresi G; Benvenga S
Histol Histopathol; 2003 Apr; 18(2):393-9. PubMed ID: 12647789
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma.
Koo BS; Kim JM; Seo ST; Yoon YH; Kwon KR; Kim SH; Kwon HW; Bae WJ; Lim YC
Ann Surg Oncol; 2014 Jul; 21(7):2310-7. PubMed ID: 24562934
[TBL] [Abstract][Full Text] [Related]
10. c-Met expression of thyroid tissue with special reference to papillary carcinoma.
Oyama T; Ichimura E; Sano T; Kashiwabara K; Fukuda T; Nakajima T
Pathol Int; 1998 Oct; 48(10):763-8. PubMed ID: 9788259
[TBL] [Abstract][Full Text] [Related]
11. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
[TBL] [Abstract][Full Text] [Related]
12. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
Zanetti A; Stoppacciaro A; Marzullo A; Ciabatta M; Fazioli F; Prat M; Comoglio PM; Baroni CD; Ruco LP
J Pathol; 1998 Nov; 186(3):287-91. PubMed ID: 10211118
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium.
Di Renzo MF; Olivero M; Serini G; Orlandi F; Pilotti S; Belfiore A; Costantino A; Vigneri R; Angeli A; Pierotti MA
J Endocrinol Invest; 1995 Feb; 18(2):134-9. PubMed ID: 7629381
[No Abstract] [Full Text] [Related]
14. Difference in patterns of Met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue.
Fluge Ø ; Haugen DR; Lillehaug JR; Varhaug JE
World J Surg; 2001 May; 25(5):623-31. PubMed ID: 11369990
[TBL] [Abstract][Full Text] [Related]
15. Expression and significance of c-met protein in papillary thyroid carcinoma.
Inaba M; Sato H; Abe Y; Umemura S; Ito K; Sakai H
Tokai J Exp Clin Med; 2002 Aug; 27(2):43-9. PubMed ID: 12472169
[TBL] [Abstract][Full Text] [Related]
16. [Differentiated thyroid carcinoma: prognostic factors].
Györy F; Lukács G; Nagy EV; Juhász F; Mezösi E; Szakáll S; Máth J; Balázs G
Magy Seb; 2001 Apr; 54(2):69-74. PubMed ID: 11339092
[TBL] [Abstract][Full Text] [Related]
17. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
18. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells.
Scarpino S; Stoppacciaro A; Ballerini F; Marchesi M; Prat M; Stella MC; Sozzani S; Allavena P; Mantovani A; Ruco LP
Am J Pathol; 2000 Mar; 156(3):831-7. PubMed ID: 10702399
[TBL] [Abstract][Full Text] [Related]
19. c-Met expression in tall cell variant papillary carcinoma of the thyroid.
Nardone HC; Ziober AF; LiVolsi VA; Mandel SJ; Baloch ZW; Weber RS; Mick R; Ziober BL
Cancer; 2003 Oct; 98(7):1386-93. PubMed ID: 14508824
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.
Scarpino S; Di Napoli A; Taraboletti G; Cancrini A; Ruco LP
J Pathol; 2005 Jan; 205(1):50-6. PubMed ID: 15526350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
